Pharvaris N.V. (PHVS) vs Viridian Therapeutics (VRDN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Pharvaris N.V. (PHVS) has outperformed Viridian Therapeutics (VRDN) over the past year, gaining 41.2% versus a loss of 13.0%. Over five years, PHVS leads with a +100.5% price change compared with +7.4% for VRDN. Pharvaris N.V. is the larger company by market cap ($2.18 billion vs $2.08 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PHVS | VRDN |
|---|---|---|
| Share price | $31.12 | $18.34 |
| Market cap | $2.18B | $2.08B |
| 1-day change | -1.77% | +0.33% |
| YTD return | +14.16% | -41.26% |
| 1-year return | +41.18% | -12.95% |
| 5-year return | +100.51% | +7.44% |
| EPS (TTM) | $-3.06 | $-3.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $43.25 | $34.29 |
| 52-week low | $20.65 | $13.18 |
| Distance from 52-week high | -28.05% | -46.52% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +83.87% | +100.38% |
| Average volume | 731.42K | 1.71M |
| Shares outstanding | 70.20M | 113.29M |
| Employees | 148 | 252 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PHVS has outperformed VRDN by 54.1 percentage points over the past year.
About Pharvaris N.V.
PHVS stock →Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant.
Health Care · Biotechnology: Pharmaceutical Preparations · 148 employees
About Viridian Therapeutics
VRDN stock →Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 252 employees
PHVS vs VRDN FAQ
Which is bigger, Pharvaris N.V. or Viridian Therapeutics?
Pharvaris N.V. (PHVS) is larger, with a market capitalization of $2.18B compared with $2.08B for Viridian Therapeutics (VRDN).
Which stock has performed better over the past year, PHVS or VRDN?
PHVS returned +41.18% over the past 12 months, compared with -12.95% for VRDN (price return, excluding dividends). Past performance does not predict future results.
Are Pharvaris N.V. and Viridian Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.